Baxter International Inc. stock (US0673431090): Down 3.2% amid conference presentation

Baxter International Inc. shares dropped 3.2% to $17.31 on May 13, 2026, following a presentation at the Bank of America Global Healthcare Conference. The stock is seen as undervalued with a GF Score of 66/100.

Baxter International Inc. stock fell 3.2% on Wednesday, May 13, 2026, closing at $17.31 after trading down from $17.89, according to StockInvest.us as of May 13, 2026. The decline coincided with the company's presentation at the Bank of America Global Healthcare Conference 2026 on the same day, as noted in Marketscreener transcript as of May 13, 2026. Investors may be assessing updates from the event amid broader healthcare sector dynamics relevant to US markets.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Baxter International
• Sector/industry: Medical Products
• Headquarters/country: United States
• Core markets: Global healthcare
• Home exchange/listing venue: NYSE (BAX)
• Trading currency: USD

Baxter International Inc.: core business model

Baxter International Inc. focuses on medical products and therapies, including renal care, hospital products, and surgical equipment. The company provides solutions for kidney disease patients and acute care settings worldwide, with a strong presence in the US healthcare system. Its business model emphasizes innovation in dialysis and infusion therapies to support hospitals and clinics.

Main revenue and product drivers for Baxter International Inc.

Key revenue streams come from the Medical Products and Therapies segment, which includes IV therapies and renal products. In recent periods, renal care has been a major driver, serving chronic kidney disease patients. The company's portfolio also features nutritional support and advanced surgery products, contributing to its position in the US hospital supply chain, according to company disclosures.

Conclusion

Baxter International Inc. stock experienced a 3.2% decline on May 13, 2026, alongside its healthcare conference presentation, highlighting ongoing market scrutiny of its medical products positioning. The company maintains a core role in renal and hospital therapies with relevance to US investors through NYSE listing and domestic exposure. Developments from such events provide insights into strategic updates amid sector competition.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.